EUVIMEDEUVIMED entdecken
Übersichtsarbeit

How DNA methylation predicts response to cancer therapies

Veronica Davalos, Gerardo Ferrer, Manel Esteller

Trends in Cancer · 2026-07 · 12 (7) · 598-620

DOI: 10.1016/j.trecan.2026.04.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2026-07. Verfasst von Veronica Davalos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain. Electronic address: vdavalos@carrerasresearch.org. Hauptthemen laut MEDLINE: DNA Methylation, Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Generalitat de Catalunya Departament d'Innovacio Universitats I Empresa, State Agency of Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant DNA methylation is a hallmark of cancer. Beyond its established diagnostic applications, growing evidence supports the utility of DNA methylation in predicting therapeutic response. By modulating gene expression patterns, particularly in pathways related to drug metabolism, DNA repair, and immune response, methylation profiles can directly influence how tumors respond to specific treatments. Although clinical implementation remains limited to a few examples, ongoing efforts to standardize assays, enhance sensitivity in liquid biopsy, and validate predictive markers in prospective trials will enable its full recognition as a dynamic, actionable decision-support tool for therapy selection and adaptive management of cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationNeoplasmsBiomarkers, TumorHumansGene Expression Regulation, NeoplasticEpigenesis, GeneticMolecular Targeted TherapyAntineoplastic Agents

Stichwörter der Autor:innen

DNA methylationcancerchemotherapyepigeneticsimmunotherapytargeted therapy

Substanzen

Biomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain. Electronic address: vdavalos@carrerasresearch.org.
  • Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain; Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, Catalonia, Spain; Karches Center for…
  • Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Cancer Epigenetics, Sant Pau Research Institute (IR Sant Pau), Barcelona, Catalonia, Spain; Institució Catalana de Recerca i Estudis Avançats (I…

Förderung

  • Instituto de Salud Carlos III
  • Generalitat de Catalunya Departament d'Innovacio Universitats I Empresa
  • State Agency of Research
  • José Carreras Leukämie-Stiftung
  • Institució Catalana de Recerca i Estudis Avançats
  • CLL Global Research Foundation
  • Ministerio de Ciencia, Innovación y Universidades
  • European Commission

Zitieren

APA

Davalos, V., Ferrer, G., & Esteller, M. (2026). How DNA methylation predicts response to cancer therapies. Trends in Cancer, 12(7), 598-620. https://doi.org/10.1016/j.trecan.2026.04.002

Vancouver

Davalos V, Ferrer G, Esteller M. How DNA methylation predicts response to cancer therapies. Trends in Cancer. 2026;12(7):598-620. doi:10.1016/j.trecan.2026.04.002

BibTeX
@article{Davalos2026,
  author = {Davalos, Veronica and Ferrer, Gerardo and Esteller, Manel},
  title = {How DNA methylation predicts response to cancer therapies},
  journal = {Trends in Cancer},
  year = {2026},
  volume = {12},
  number = {7},
  pages = {598--620},
  doi = {10.1016/j.trecan.2026.04.002}
}
Kostenlos starten →